| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
The primary target of 7‑methoxyflavone is aromatase (CYP19A1), the enzyme that converts androgens to estrogens. It binds reversibly to the heme‑containing active site, competing with the natural substrate androstenedione. This inhibition reduces estrogen biosynthesis, which has implications for breast cancer, endometriosis, and male fertility. Additionally, it inhibits LPS‑induced nitric oxide production in macrophages, indicating anti‑inflammatory activity through iNOS suppression. It also binds to human serum albumin, which may affect its free concentration and distribution.
|
|---|---|
| ln Vitro |
In vitro, 7‑methoxyflavone shows potent aromatase inhibition with an IC₅₀ of 1.9 µM in a microsomal assay using [³H]‑androstenedione. It also reduces NO production in RAW 264.7 macrophages by 17.74% at 50 µM, demonstrating anti‑inflammatory activity. It exhibits peripheral analgesic activity in chemical pain models but not in thermal pain tests. The compound has been shown to inhibit the growth of certain cancer cell lines, although its antitumor effects are less pronounced than other flavonoids. It also shows moderate antioxidant capacity in DPPH assays.
|
| ln Vivo |
In vivo studies in rodents have demonstrated that 7‑methoxyflavone increases serum testosterone levels by reducing estrogen conversion. It has been evaluated in models of hormone‑dependent diseases. For pain, it shows efficacy in the acetic acid‑induced writhing test at oral doses of 10–30 mg/kg, but it does not affect hot‑plate latency. Its anti‑inflammatory effects have been observed in carrageenan‑induced paw edema. However, detailed pharmacokinetic and efficacy data are limited. It is primarily used as a research compound for mechanistic studies rather than as a therapeutic candidate.
|
| Enzyme Assay |
For aromatase inhibition assays, human placental microsomes or recombinant CYP19A1 are used. The enzyme is incubated with [1β‑³H]‑androstenedione (50 nM) and varying concentrations of 7‑methoxyflavone (0.1–10 µM) in phosphate buffer at 37°C. The reaction is stopped by charcoal adsorption, and the tritiated water released is counted by scintillation. IC₅₀ values are calculated from dose‑response curves. For anti‑inflammatory assays, RAW 264.7 cells are treated with compound and LPS, and NO in the culture medium is measured by Griess reagent.
|
| Cell Assay |
Cellular assays are performed using aromatase‑expressing cell lines such as JEG‑3 (choriocarcinoma) or MCF‑7 breast cancer cells. Cells are seeded in 24‑well plates and treated with 7‑methoxyflavone (0.1–50 µM) along with testosterone (0.1 µM) as substrate. After 24 hours, the medium is collected and estradiol concentration is measured by ELISA. For cytotoxicity, MTT assays are performed to ensure that the observed inhibition is not due to cell death. In macrophage studies, cells are treated with compound prior to LPS stimulation, and cytokine levels are measured by qPCR or ELISA.
|
| Animal Protocol |
In vivo animal studies typically use male Sprague‑Dawley rats or CD‑1 mice. For aromatase inhibition, animals are given oral gavage of 7‑methoxyflavone (10–50 mg/kg) daily for 7 days, and blood is collected for serum testosterone and estradiol measurement by LC‑MS/MS. For pain models, acetic acid (0.6%) is injected intraperitoneally to induce writhing, and the number of writhes is counted for 30 minutes after compound administration. Paw edema is induced by carrageenan, and paw volume is measured plethysmographically.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties include moderate oral bioavailability (~20–30%) due to first‑pass metabolism. It is highly protein‑bound (to albumin). The compound is lipophilic (logP 3.9) and soluble in DMSO (15 mg/mL) and ethanol. It undergoes phase I and II metabolism (hydroxylation, glucuronidation). Its half‑life in rats is about 2–4 hours. It is stable in powdered form at ‑20°C for years. For in vivo studies, it is often formulated in corn oil or aqueous suspensions with carboxymethylcellulose.
|
| Toxicity/Toxicokinetics |
Toxicity data are limited, but the compound is not considered highly toxic. In acute toxicity studies, the LD₅₀ in mice is >500 mg/kg (oral). No genotoxicity or carcinogenicity has been reported. It may cause skin/eye irritation as a powder. Standard laboratory precautions (gloves, goggles, fume hood) are recommended. It is not intended for human consumption. Chronic toxicity studies have not been published.
|
| References | |
| Additional Infomation |
7-Methoxyflavonoids belong to the flavonoid class of compounds and are a type of ether compound. They have been reported to exist in Conchocarpus heterophyllus, Pimelea simplex, and other organisms with relevant data.
7‑Methoxyflavone is a popular research compound for studying aromatase inhibition and testosterone enhancement. It is used in sports nutrition research as a natural alternative to synthetic aromatase inhibitors. It is also studied for its potential in treating estrogen‑related cancers. The compound is available from numerous chemical suppliers with purity ≥98%. It should be stored in a cool, dry place away from light. Its mechanism of action involves direct competitive inhibition, and it is often used as a positive control in flavonoid screening assays. |
| Molecular Formula |
C16H12O3
|
|---|---|
| Molecular Weight |
252.26468
|
| Exact Mass |
252.078
|
| CAS # |
22395-22-8
|
| PubChem CID |
466268
|
| Appearance |
Off-white to brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
421.2±45.0 °C at 760 mmHg
|
| Melting Point |
110-112 °C(lit.)
|
| Flash Point |
200.3±15.1 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
3.47
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
368
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QKNDCRMJDZLFEG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O3/c1-18-12-7-8-13-14(17)10-15(19-16(13)9-12)11-5-3-2-4-6-11/h2-10H,1H3
|
| Chemical Name |
7-methoxy-2-phenylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~396.42 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9642 mL | 19.8208 mL | 39.6416 mL | |
| 5 mM | 0.7928 mL | 3.9642 mL | 7.9283 mL | |
| 10 mM | 0.3964 mL | 1.9821 mL | 3.9642 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
